Pfizer Prevails in Norwegian Lipitor Patent Challenge
In response to the decision, Jeffrey B. Kindler, Pfizer's vice chairman and general counsel, said, "We are pleased with the court's decision, which is a victory not only for Pfizer, but for all innovators pursuing high-risk medical discoveries." Ranbaxy can appeal the decision, but it will not be able to market a product made using the patented intermediate compounds unless it prevails on appeal.
Separately, the Court also ruled that another Pfizer patent, covering a process for converting crystalline atorvastatin to amorphous atorvastatin, is valid but not infringed by Ranbaxy in Norway.
Pfizer said it will continue to vigorously defend its intellectual property rights against infringement anywhere around the globe.
Most read news
Other news from the department politics & laws
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.